Clinical Trial Update: Romosozumab Versus Denosumab in GIOP: a 2-year Extension Study [Phase 4]

View source ↗

Summary

Phase 4 extension trial comparing romosozumab versus denosumab in glucocorticoid-induced osteoporosis to assess two-year outcomes; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glucocorticoid-induced Osteoporosis
• Osteoporosis

Drugs mentioned

• Evenity (romosozumab)
• Prolia (denosumab)

Snippet

Sponsor: Tuen Mun Hospital | Conditions: Osteoporosis, Glucocorticoids Toxicity | Phase 4 | Status: RECRUITING